title: Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors.
abstract: Ovarian cancer is the deadliest of the gynecological diseases and the fifth cause of cancer death among American women. This is mainly due to the lack of prognostic tools capable of detecting early stages of ovarian cancer and to the high rate of resistance to the current chemotherapeutic regimens. In this scenario the overall 5-year survival rate for ovarian cancer patients diagnosed at late stage is less than 25%. Abnormalities associated with the malignant phenotype and the mechanisms of tumor progression are not clearly understood. In vitro studies are necessary, yet have been hampered due to the limitations accompanied with the use of ovarian cancer cell lines and the heterogeneity of the ovarian cancer cell population derived from ascites fluids. In this study we present a simple, rapid and reproducible method for the isolation and characterization of ovarian cancer cells from solid tumor tissue and show that enzymatic digestion for 30 minutes with dispase II results in the most effective recovery of viable epithelial ovarian cancer (EOC) cells. The resulting cancer (EOC) cell preparations demonstrate a significant yield, high levels of viability and are fibroblast-free. They grow for up to six passages and retain the capacity of forming spheroids-like structures in agarose. In addition, they can be genetically manipulated and used for drug screening, thus rendering them highly suitable for downstream applications. Notably, isolation of ovarian cancer cells from solid specimens using this method has the advantage of allowing for isolation of cancer cells from early stages of ovarian cancer as well as obtaining cells from defined either primary and/or metastatic ovarian cancer sites. Thus, these cells are highly suitable for investigations aimed at understanding ovarian cancer.
authors.affiliation: Departments of Obstetrics, Gynecology and Women's Heath, University of Minnesota, Minneapolis, Minnesota, United States of America.
authors.forename: Thanasak
authors.initials: T
authors.lastname: Sueblinvong
authors.forename: Rahel
authors.initials: R
authors.lastname: Ghebre
authors.forename: Yoshie
authors.initials: Y
authors.lastname: Iizuka
authors.forename: Stefan E
authors.initials: SE
authors.lastname: Pambuccian
authors.forename: Rachel
authors.initials: R
authors.lastname: Isaksson Vogel
authors.forename: Amy P N
authors.initials: AP
authors.lastname: Skubitz
authors.forename: Martina
authors.initials: M
authors.lastname: Bazzaro
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000378:metabolism; D000077216:Carcinoma, Ovarian Epithelial; D015815:Cell Adhesion Molecules / Q000378:metabolism; D018929:Cell Culture Techniques / Q000379:methods*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002469:Cell Separation / Q000379:methods*; D004354:Drug Screening Assays, Antitumor; D000071858:Epithelial Cell Adhesion Molecule; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000378:metabolism / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology*; D010641:Phenotype; D013997:Time Factors
chemical_list: D000951:Antigens, Neoplasm; D015815:Cell Adhesion Molecules; D000071858:Epithelial Cell Adhesion Molecule